Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-13
2006-06-13
Saeed, Kamal A. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07060844
ABSTRACT:
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
REFERENCES:
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6541504 (2003-04-01), Andrews et al.
patent: 6699863 (2004-03-01), Andrews et al.
patent: 6747025 (2004-06-01), Andrews et al.
patent: 2004/0198802 (2004-10-01), Andrews et al.
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO99/10325 (1999-03-01), None
Plowman et al, “Receptor Tyrosine Kinases as Targets for Drug Intervention”, 1994, DN&P 7(6): 334-339.
Bolen, “Nonrecptor tyrosine protein kinases”, 1993, Oncogen 8: 2025-2031.
Kendall et al, “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor”, 1994, Proc. Natl'l Acad. Sci 90: 10705-10709.
Takano et al, “Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase C.”, 1993, Mol. Bio. Cell 4: 2072, p. 358A.
Kinsella et al, “Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel”, 1992, Experimental Cell Research, 199: 56-62.
Wright et al, “Inhibition of Angiogenesis In Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032”, 1992, Journal of Cellular Phys. 152: 448-457.
Mariani et al, “Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor”,1994, Proc. Am. Assoc. Cancer Res. 35:2268; p. 381.
Kim et al, “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo”, Nature 362, 841-844, Apr. 29, 1993.
Jellinek et al, “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor”, Biochemistry 33: 10450-10456, 1994.
Andrews Steven W.
Guo Xialing
Hull, III Clarence E.
Malone Thomas
Wang Edward H.
Allergan Inc.
Anderson Rebecca
Baran Robert J.
Johnson Brent A.
Saeed Kamal A.
LandOfFree
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3649257